The Liver Meeting 2024 - Debrief Sessions - Portuguese-Choleostasis Debrief Session

Video Transcription

Video Summary

Dr. Aparna Goel, an Associate Professor at Stanford University, presented recent advances in cholestatic liver diseases, focusing on conditions like primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC). She highlighted the approval of novel therapies such as alofibrinol and celadelpar for PBC and examined current treatment practices through global studies. Key discussions included treatment goals, especially alkaline phosphatase levels, and new insights into the management of advanced fibrosis. The talk also covered emerging treatments for PSC, including Bexotograst and CM101, which target fibrosis and inflammation with promising early results. Furthermore, she discussed the importance of managing cholestatic pruritus as part of overall patient care, referencing trials on IBAT inhibitors and the effectiveness of new PPARs. Finally, Dr. Goel touched on autoimmune hepatitis research, suggesting that anti-TNF therapy could be a promising corticosteroid-free treatment option, indicating an exciting future landscape in liver disease therapeutics.

Keywords

cholestatic liver diseases

primary biliary cholangitis

primary sclerosing cholangitis

novel therapies

fibrosis management

autoimmune hepatitis